Comparative clinical effectiveness and safety of tobacco cessation pharmacotherapies and electronic cigarettes: a systematic review and network meta‐analysis of randomized controlled trials
Authors:
- Kyla H. ThomasKTKyla H. Thomas
- Michael N. DaliliMDMichael N. Dalili
- José A. López‐LópezJLJosé A. López‐López
- Edna KeeneyEKEdna Keeney
- David M. PhillippoDPDavid M. Phillippo
- Marcus R. MunafòMMMarcus R. Munafò
- Matt StevensonMSMatt Stevenson
- Deborah M. CaldwellDCDeborah M. Caldwell
- Nicky J. WeltonNWNicky J. Welton
Open Access
Abstract
Aim: To determine how varenicline, bupropion, nicotine replacement therapy (NRT) and electronic cigarettes compare with respect to their clinical effectiveness and safety.Method: Systematic reviews and Bayesian network meta‐analyses of randomized controlled trials, in any setting, of varenicline, bupropion, NRT and e‐cigarettes (in high, standard and low doses, alone or in combination) in adult smokers and smokeless tobacco users with follow‐up duration of 24 weeks or greater (effectiveness) or any duration (safety). Nine databases were searched until 19 February 2019. Primary outcomes were sustained tobacco abstinence and serious adverse events (SAEs). We estimated odds ratios (ORs) and treatment rankings and conducted meta‐regression to explore covariates.Results: We identified 363 trials for effectiveness and 355 for safety. Most monotherapies and combination therapies were more effective than placebo at helping participants to achieve sustained abstinence; the most effective of these, estimated with some imprecision, were varenicline standard [OR = 2.83, 95% credible interval (CrI) = 2.34–3.39] and varenicline standard + NRT standard (OR = 5.75, 95% CrI = 2.27–14.88). Estimates were higher in smokers receiving counselling than in those without and in studies with higher baseline nicotine dependence scores than in those with lower scores. Varenicline standard + NRT standard showed a high probability of being ranked best or second‐best. For safety, only bupropion at standard dose increased the odds of experiencing SAEs compared with placebo (OR = 1.27, 95% CrI = 1.04–1.58), and we found no evidence of effect modification.Conclusions: Most tobacco cessation monotherapies and combination therapies are more effective than placebo at helping participants to achieve sustained abstinence, with varenicline appearing to be most effective based on current evidence. There does not appear to be strong evidence of associations between most tobacco cessation pharmacotherapies and adverse events; however, the data are limited and there is a need for improved reporting of safety data.Keywords
Funding Information
- National Institute for Health Research
- Health Technology Assessment Programme (15/58/18)
- Studium – Prospero Alapítvány (CRD42016041302)
This publication has 43 references indexed in Scilit:
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Treating heavy smokers in primary care with the nicotine nasal spray: randomized placebo‐controlled trialAddiction, 2011
- Psychiatric Adverse Events in Randomized, Double-Blind, Placebo-Controlled Clinical Trials of VareniclineDrug Safety, 2010
- Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research DatabaseBMJ, 2009
- Safety and Drug Utilization Profile of Varenicline as Used in General Practice in EnglandDrug Safety, 2009
- The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trialCurrent Medical Research and Opinion, 2008
- Efficacy and tolerability of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokersClinical Therapeutics, 2007
- What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse dataStatistics in Medicine, 2004
- Sifting the evidence---what's wrong with significance tests? Another comment on the role of statistical methodsBMJ, 2001
- A random‐effects regression model for meta‐analysisStatistics in Medicine, 1995